A Phase 2 Study of Enasidenib in People With T-Cell Lymphoma

Full Title

Purpose

Researchers want to see how well the drug enasidenib works in people with angioimmunoblastic T-cell lymphoma (AITL). The people in this study have AITL that came back or keeps growing after treatment. Their cancers also have a mutation (change) in the IDH2 gene.

Enasidenib blocks the mutated IDH2 protein. This blocking action may improve your blood cell counts and stop or slow the growth of cancer cells. Enasidenib is taken orally (by mouth).

People who also have B-cell lymphoproliferation will get rituximab with enasidenib. With B-cell lymphoproliferation, there is uncontrolled growth of white blood cells called lymphocytes in the blood or lymph nodes. Rituximab is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Zachary Epstein-Peterson’s office at 646-608-4176.